Syndesi Therapeutics

Scroll
Investment area
Novo Seeds
Region
Europe
Date of investment
December 2017
Website
http://www.syndesitherapeutics.com/

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.